Evidenced-Based Prior for Estimating the Treatment Effect of Phase III Randomized Trials in Oncology
By enabling computation of contextual probabilities for the treatment effect from summary statistics, our robust, highly practical tool, now posted on a user-friendly webpage, can aid the wider oncology community in the interpretation of phase III trials.
Authors
- Timothy A. Lin (ORCID: https://orcid.org/0000-0003-4183-9120)
- Alexander D. Sherry (ORCID: https://orcid.org/0000-0001-5115-1691)
- Ethan B. Ludmir (ORCID: https://orcid.org/0000-0002-5472-5344)
- Zachary R. McCaw (ORCID: https://orcid.org/0000-0002-2006-9828)
- Joseph Abi Jaoude (ORCID: https://orcid.org/0000-0002-2283-4765)
- Erik W. van Zwet (ORCID: https://orcid.org/0000-0001-5537-3179)
- Ramez Kouzy (ORCID: https://orcid.org/0000-0002-1521-0495)
- Pavlos Msaouel (ORCID: https://orcid.org/0000-0001-6505-8308)
- Gabrielle S. Kupferman (ORCID: https://orcid.org/0000-0003-2088-4395)
Institutions
- University of North Carolina at Chapel Hill (US)
- The University of Texas MD Anderson Cancer Center (US)
- Johns Hopkins University (US)
- Johns Hopkins Medicine (US)
- Leiden University Medical Center (NL)
- Stanford University (US)
Publication Details
- Journal
- JCO Precision Oncology
- Published
- 2024-09-30
- DOI
- https://doi.org/10.1200/po.24.00363
- Citations
- 9
- Primary Topic
- Statistical Methods in Clinical Trials
- Type
- article
- Field-Weighted Citation Impact
- 6.38
Funders
- University of Texas MD Anderson Cancer Center
- National Cancer Institute